Mitchell Freeman insider trades: Medis Technologies (MDTL) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Mitchell reports to the SEC
Open-market buys and sales
3 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Nov 5, 2009 | MDTL | ↓ Sell | 25,256 | $0.16 | $4K | Direct | Nov 9, 2009 (4d) |
| May 10, 2006 | MDTL | ↓ Sell | 6,000 | $33.43 | $201K | Direct | May 10, 2006 (0d) |
| May 4, 2006 | MDTL | ↓ Sell | 4,000 | $30.08 | $120K | Direct | May 4, 2006 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Mitchell Freeman's insider trades
Mitchell Freeman is a director at Medis Technologies (MDTL). Since May 4, 2006, Mitchell has reported no open-market purchases and 3 sales worth $325K on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (7 filings), option exercises (3 filings), shares returned to the company (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every MDTL insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.